论文部分内容阅读
目的:评价孟鲁司特钠对小儿咳嗽变异性哮喘患者的临床疗效。方法:选取2013年10月—2014年8月间收治的咳嗽变异性哮喘患儿80例,根据其临床治疗用药不同,将其分为观察组及对照组,每组40例;对照组患儿均给予临床常规治疗方法治疗,观察组患儿在对照组常规治疗基础上加用孟鲁司特钠治疗,比较两组患儿的临床疗效。结果:治疗后,观察组患儿的总有效率为92.50%显著高于对照组为80.00%(P<0.05);观察组患儿哮喘缓解时间、哮喘消失时间均显著短于对照组(P<0.05);观察组患儿不良反应的发生率为15.00%和复发率为7.50%,对照组患儿不良反应的发生率为2.50%和复发率为20.00%,经比较其差异均有统计学意义(P<0.05)。结论:孟鲁司特钠用于治疗小儿咳嗽变异性哮喘患者的临床疗效较为显著。
Objective: To evaluate the clinical efficacy of montelukast sodium in children with cough variant asthma. Methods: Totally 80 children with cough variant asthma admitted from October 2013 to August 2014 were divided into observation group and control group according to the different clinical medication, 40 cases in each group. Children in control group All patients in the observation group were treated with montelukast sodium on the basis of routine treatment in the control group, and the clinical efficacy of the two groups was compared. Results: After treatment, the total effective rate in the observation group was 92.50%, which was significantly higher than that in the control group (80.00%, P <0.05). The asthma relief time and asthma disappearance time in the observation group were significantly shorter than those in the control group (P < 0.05). The incidence of adverse reactions in the observation group was 15.00% and the recurrence rate was 7.50%. The incidence of adverse reactions in the control group was 2.50% and the recurrence rate was 20.00%. The differences were statistically significant (P <0.05). Conclusion: The clinical efficacy of montelukast sodium for the treatment of children with cough variant asthma is more significant.